Global Health Shakeup: WHO Funds Ebola, US Aid Impact, and Pharma Updates

A series of health updates include WHO's funding for Uganda's Ebola response, CDC's isolation of a mpox patient in New York, and promising results from Ozempic for alcohol use disorder. WHO critiques U.S. aid pause impacting global health, while Italian drug maker Recordati and GE HealthCare announce profit forecasts.

In a series of recent health developments, WHO has released an additional $2 million to aid Uganda's fight against the Ebola outbreak, which has claimed one life and infected at least eight others, according to Director-General Tedros Adhanom Ghebreyesus.

The CDC announced a patient's isolation in New York after a diagnosis with the new mpox variant, clade1b, as authorities are tracking possible contacts. Encouraging findings also emerged from a small trial of Novo Nordisk’s diabetes drug Ozempic, which suggested potential benefits for those with alcohol use disorder.

Global health challenges have been further impacted by U.S. aid funding pauses, affecting programs like polio and HIV, said WHO's Ghebreyesus. Meanwhile, Recordati raised its profit forecasts, anticipating strong growth, while GE HealthCare is banking on steady demand for its medical devices. The sector remains dynamic and rapidly evolving.